SBTX Silverback Therapeutics

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights.

Dial-in information for conference participants may be obtained by . To access the webcast and slides, please visit the page in the Investors & Media section of the Company’s . A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit .

Investor Contact:

Justin Chakma, ARS Pharma

Monique Allaire, THRUST

Media Contact:

Christy Curran, Sam Brown Inc.



615.414.8668



EN
04/08/2025

Underlying

SBTXSilverback Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silverback Therapeutics

 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clini...

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting -Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients’ dislike of needle-based administration, the value of a nasal option increased by mor...

February 10, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

California K-12 Schools Now Eligible for neffyinSchools Program, Offer...

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that California, the state where ARS Pharma is headquartered, is now eligible for its nef...

January 21, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

neffy® (epinephrine nasal spray) Approved in China as the First and On...

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name 优敏速®, expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharma...

December 29, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Health...

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York. Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in a fireside ch...

November 26, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and H...

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even Conference call to be held today, November 10, 2025, at ...

November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch